Engineering Biopharmaceuticals - An overall increasing proportion of future product approvals will be engineered in some way, either directly or indirectly.

Engineering Biopharmaceuticals - An overall increasing proportion of future product approvals will be engineered in some way, either directly or indirectly. - BioPharm International

home: :

rss feeds/xml

Email Print

Save License

Engineering Biopharmaceuticals

An overall increasing proportion of future product approvals will be engineered in some way, either directly or indirectly.

Nov 1, 2007
By: Gary Walsh, PhD
BioPharm International
Volume 20, Issue 11

« Previous

1 2 34

6. Li, H., Sethuraman, N., Stadheim, T., Zha, D., Prinz, B. et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat. biotechnol. 2006;24:210–215.

7. Jefferis, R. Glycosylation of recombinant antibody therapeutics. Biotechnol. Progress, 2005;21:11–16.

8. Satoh, M., Iida, S. and Shitara, K. Non-fucosylated therapeutic antibodies as next generation therapeutic antibodies. Exp. Op. Biol. Ther. 2006;6:1161–1173.

« Previous

1 2 34

blog comments powered by Disqus

About the Author

Gary Walsh, PhD

gary.walsh@ul.ie

Associate Professor in the Industrial Biochemistry Program at the University of Limerick. He is also a member of BioPharm International's Editorial Advisory Board. Articles by Gary Walsh, PhD